Moderna’s oncology story got a fresh set of numbers last week. Wall Street’s response has been anything but uniform — and that divergence, rather than any single headline, is the more instructive signal for investors trying to work out what the shares are actually worth.
The clinical foundation is solid enough. Moderna and Merck published detailed results from the Phase 3 INTerpath-001 trial, testing intismeran autogene alongside pembrolizumab in patients whose melanoma had been fully removed. The combination cut the risk of melanoma recurrence or death by 42% versus Keytruda alone, with a hazard ratio of 0.58. The risk of distant metastasis or death fell 38%, hazard ratio 0.62. The study enrolled patients with stage IIB through IV melanoma. At the presentation, Moderna put the 24-month recurrence-free survival rate at 82.2% for the combination against 70.0% for pembrolizumab on its own — a comparison that makes the treatment benefit far more tangible than a standalone risk-reduction figure.
Those results had already seen the light of day early, after a data leak forced their hand. And by several media accounts, they landed short of the earlier Phase 2 readout that had set expectations running high. Reuters characterised the ensuing selloff as profit-taking once the news was out.
Two Houses, Two Conclusions
Monday brought the analyst reaction, and it pointed in both directions at once. Piper Sandler lifted its price target to $230 from $167 while keeping an Overweight rating — a firmly bullish stance, though the positive recommendation predated the target hike. William Blair moved the other way, downgrading Moderna from Outperform to Market Perform and citing valuation after the strong rally.
Neither call settles the argument. A price target condenses one house’s view; it does not validate the assumptions beneath it, nor does it tell you what expectations are already baked into the share price. Picking only the higher target ignores the more cautious position, and fixating on the downgrade erases the optimism that persists elsewhere. What emerges is a valuation dispute, not a directional verdict.
Should investors sell immediately? Or is it worth buying Moderna?
The stock’s own recent trading reflects that tension. Shares slipped 0.6% to €184.28 on one session, then gained 4.9% the next day. A single day’s move neither refutes the cautious analysts nor confirms the raised target.
What the Insider Filing Does — and Doesn’t — Say
Separately, a regulatory filing disclosed a share sale by President Stephen Hoge. According to the mandatory SEC notice, Hoge reported the sale of 39,145 shares at a weighted average price of $220.72 on 15 October. The transaction was executed under a Rule 10b5-1 trading plan adopted on 15 June, and the filing also notes option exercises connected to the reported sales. A pre-arranged plan of this kind is a scheduled disposition, not a signal about management’s read on the pipeline.
The medical evidence and the market’s appraisal of it deserve to be judged on separate tracks. A 42% risk reduction describes a clinical comparison; it is not a revenue forecast, and it sets no benchmark for how far the stock ought to travel. Good science and an attractive valuation are not the same thing, and at Moderna the gap between them is where the real debate sits.
The next hard checkpoint is corporate rather than clinical. Moderna will report third-quarter 2026 results on 6 November 2026 and hold a conference call, giving investors a chance to set the pipeline progress alongside the actual business numbers. Until then, the study data carry weight; the price targets warrant distance.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 28 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 28.
Moderna: Buy or sell? Read more here...
